The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
The canola line 23-18-17 was genetically engineered to express
modified seed fatty acid content, specifically high levels of
lauric acid and myristic acid. The increased levels of lauric acid
in oil from the modified canola lines allow for its use as a
replacement for other lauric acid oils, such as coconut and palm
kernel oil, in products such as confectionery coatings and
fillings, margarines, spreads, shortenings and commercial frying
The modified fatty acid content of 23-18-17 is a result of the
insertion of a thioesterase (TE) encoding gene from the California
bay tree, Umbellularia californica, which is an alternative source
of the spice "bay leaf" that is harvested commercially from Lauris
nobilis. The introduced thioesterase enzyme is active in the fatty
acid biosynthetic pathway of the developing seed and causes the
accumulation of triacylglycerides containing esterified lauric acid
and, to a lesser extent, myristic acid.
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Brassica napus - Turnip, Rapeseed, Canola Plant, Oilseed Rape, Rape, BRANA
CGN-89465-2 - High oleic acid canola
Production of medical or pharmaceutical compounds (human or animal) - Omega-3 fatty acids (e.g. DHA)
Resistance to antibiotics - Kanamycin
- Agrobacterium-mediated DNA transfer
Napin gene terminator
Neomycin Phosphotransferase II
Tumour Morphology Large gene terminator
The original transformation event 23 was estimated to have 15
copies of the genes, at five independent genetic loci, as shown by
Southern and segregation analyses. Lines 23-198 and 23-18-17 are
several generations removed from the original transformant.
Mendelian inheritance, and Southern and PCR analyses of
third-generation material show the stability of the introduced
genes as the bands did not change position. Some of the copies are
segregating out, as expected, so that these lines may not be
homogeneous for the number of copies present.
- Production of medical or pharmaceutical compounds (human or animal)
- Omega-3 fatty acids (e.g. DHA)
- Resistance to antibiotics